

Summary statistics - quantitative results

(Groups: manufacturer of instrument)

Filter: minimal size of the groups n = 5

EQA round: AP2/22 - Antithrombotic Agents

Deadline: 16.09.2022

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of the participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability												
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}
Set 1														
(108) Apixaban						31						31	30	97%
Samples and groups		[µg/L]												
Sample A1							CVP							
(38) IL		74,5	9,3	13	31		74,5	4,1	25%	55,8	93,2	31	30	97%
(63) Sysmex		82,3	2,2	2,7	10	0						10		
(94) Stago		70,2	8,0	11	13	0						13		
Other		69,0	5,9	8,6	6	0						6		
					2	0						2		
							1x 162, 1x 179							
Sample B1							CVP							
(38) IL		294	21	7,2	31		294	9,3	25%	220	368	31	31	100%
(63) Sysmex		306	7,3	2,4	10	0						10		
(94) Stago		279	24	8,6	13	0						13		
Other		304	14	4,6	6	0						6		
					2	0						2		
							1x 162, 1x 179							
Set 2														
(109) Dabigatran						34						34	30	88%
Samples and groups		[µg/L]												
Sample A2							CVP							
(38) IL		44,8	5,4	12	34		44,8	2,3	25%	33,6	56	34	30	88%
(63) Sysmex		47,5	2,3	4,9	12	0						12		
Other		44,5	9,3	21	15	0						15		
					7	0						7		
							4x 94, 1x 149, 1x 162, 1x 179							
Sample B2							CVP							
(38) IL		223	22	10	34		223	9,4	25%	167	279	34	33	97%
(63) Sysmex		217	19	8,6	12	0						12		
Other		222	21	9,6	15	0						15		
					7	0						7		
							4x 94, 1x 149, 1x 162, 1x 179							
Set 3														
(110) Rivaroxaban						38						38	37	97%
Samples and groups		[µg/L]												
Sample A3							CVP							
(38) IL		73,0	6,3	8,6	38		73	2,5	25%	54,7	91,3	38	37	97%
(63) Sysmex		75,0	6,4	8,5	12	0						12		
(94) Stago		72,6	7,4	10	17	0						17		
Other		68,7	2,0	2,9	6	0						6		
					3	0						3		
							1x 149, 1x 162, 1x 179							
Sample B3							CVP							
(38) IL		299	28	9,4	38		299	11	25%	224	374	38	38	100%
(63) Sysmex		278	14	5,0	12	0						12		
(94) Stago		311	22	7,0	17	0						17		
Other		303	9,3	3,1	6	0						6		
					3	0						3		
							1x 149, 1x 162, 1x 179							

st_kn_p

End of report

Printed: 21.09.2022